Factors aggravating the course of atrial fibrillation in comorbid hypertension and type 2 diabetes mellitus

Authors

DOI:

https://doi.org/10.14739/2310-1210.2022.3.253819

Keywords:

atrial fibrillation, hypertension, diabetes mellitus, comorbidity

Abstract

Atrial fibrillation (AF) is quite a common problem, and its frequency increases with age. The course of this rhythm disturbance in comorbid conditions of hypertension and diabetes mellitus (DM) may depend on many pathophysiological factors. Therefore, the study on factors of AF development and aggravation in these comorbidities remains relevant.

Aim. The work aimed at determining the factors of development and aggravation of AF in patients with hypertension and type 2 DM.

Materials and methods. 214 patients with AF, hypertension and type 2 DM were examined. They were distributed into groups: 1) isolated AF – 7.5 %; 2) AF and hypertension – 51.9 %; 3) AF, hypertension and DM – 25.2 %; 4) isolated hypertension – 5.1 %; 5) hypertension and DM – 10.3 %. The paroxysmal form of AF was revealed in 34.3 %, persistent – in 46.4 % and constant – in 19.3 %.

Results. It was revealed that persons with taller stature experienced arrhythmia symptoms more frequently (P = 0.01). Sex, Quetelet index, height, duration of hypertension, SBP, glucose, glycated Hb, urea, fibrinogen, triglycerides, interventricular septum and left ventricular posterior wall thickness, LV ejection fraction, concentric type of remodeling influenced the development of next AF episode in conditions of comorbid hypertension and DM. Quetelet index (P = 0.03), duration of AH (P = 0.03), and glycated Hb level (P = 0.002) were the most significant factors for frequent AF recurrences.

A history of at least one AF episode increased the risk of developing a subsequent one by 5.56 times (Р = 0.01). An increase in LA was significantly influenced by AF. Hypertension also contributed to cardiac remodeling, namely, its hypertrophy, while the presence of DM only enhanced this effect. The increase in LА over 4.43 cm (P = 0.0001) and RV over 2.59 cm (P = 0.02) significantly increased the risk of АF conversion to the permanent form.

Conclusions. A special attention should be paid to such parameters as Quetelet index, duration of AH, elevated BP, daily SBP variability, glycated Hb level and fasting glycemia, echocardiography indexes (EF, size of LA and RV) to prevent the occurrence of AF and its chronicity in patients with hypertension and DM.

Author Biographies

M. V. Hrebenyk, Ivan Horbachevsky Ternopil National Medical Universityof the Ministry of Health of Ukraine

MD, PhD, DSc, Professor of the Department of Therapy and Family Medicine, Faculty of Postgraduate Education

Yu. V. Honcharyk, Ivan Horbachevsky Ternopil National Medical Universityof the Ministry of Health of Ukraine

MD, Postgraduate student of the Department of Therapy and Family Medicine, Faculty of Postgraduate Education

References

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S. E., Kreutz, R., Laurent, S., Lip, G., … ESC Scientific Document Group. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, 39(33), 3021-3104. https://doi.org/10.1093/eurheartj/ehy339

Akoum, N., Mahnkopf, C., Kholmovski, E. G., Brachmann, J., & Marrouche, N. F. (2018). Age and sex differences in atrial fibrosis among patients with atrial fibrillation. EP Europace, 20(7), 1086-1092. https://doi.org/10.1093/europace/eux260

Ceornodolea, A. D., Bal, R., & Severens, J. L. (2017). Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. Stroke Research and Treatment, 2017, Article 8593207. https://doi.org/10.1155/2017/8593207

Ostchega, Y., Fryar, C. D., Nwankwo, T., & Nguyen, D. T. (2020). Hypertension Prevalence Among Adults Aged 18 and Over: United States, 2017-2018. NCHS data brief, (364), 1-8.

Ampofo, A. G., & Boateng, E. B. (2020). Beyond 2020: Modelling obesity and diabetes prevalence. Diabetes Research and Clinical Practice, 167, Article 108362. https://doi.org/10.1016/j.diabres.2020.108362

Aune, D., Feng, T., Schlesinger, S., Janszky, I., Norat, T., & Riboli, E. (2018). Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. Journal of Diabetes and its Complications, 32(5), 501-511. https://doi.org/10.1016/j.jdiacomp.2018.02.004

University of Pennsylvania School of Medicine. (2019, November 13). Taller people have increased risk for developing atrial fibrillation: Height is a causal risk factor for AFib: Study. ScienceDaily. https://www.sciencedaily.com/releases/2019/11/191113092606.htm

Przewłocka-Kosmala, M., Jasic-Szpak, E., Rojek, A., Kabaj, M., Sharman, J. E., & Kosmala, W. (2019). Association of central blood pressure with left atrial structural and functional abnormalities in hypertensive patients: Implications for atrial fibrillation prevention. European Journal of Preventive Cardiology, 26(10), 1018-1027. https://doi.org/10.1177/2047487319839162

Masci, A., Barone, L., Dedè, L., Fedele, M., Tomasi, C., Quarteroni, A., & Corsi, C. (2019). The Impact of Left Atrium Appendage Morphology on Stroke Risk Assessment in Atrial Fibrillation: A Computational Fluid Dynamics Study. Frontiers in Physiology, 9, Article 1938. https://doi.org/10.3389/fphys.2018.01938

Brandes, A., Smit, M. D., Nguyen, B. O., Rienstra, M., & Van Gelder, I. C. (2018). Risk Factor Management in Atrial Fibrillation. Arrhythmia & Electrophysiology Review, 7(2), 118-127. https://doi.org/10.15420/aer.2018.18.2

Lee, S. R., Park, C. S., Choi, E. K., Ahn, H. J., Han, K. D., Oh, S., & Lip, G. (2021). Hypertension Burden and the Risk of New-Onset Atrial Fibrillation: A Nationwide Population-Based Study. Hypertension, 77(3), 919-928. https://doi.org/10.1161/HYPERTENSIONAHA.120.16659

Li, Z., Wang, Z., Yin, Z., Zhang, Y., Xue, X., Han, J., Zhu, Y., Zhang, J., Emmert, M. Y., & Wang, H. (2017). Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation. Oncotarget, 8(32), 53714-53729. https://doi.org/10.18632/oncotarget.16342

Kyselov, S. M. (2021). Suchasni uiavlennia shchodo predyktoriv vynyknennia ta prohresuvannia fibryliatsii peredserd [Current concepts on predictors of atrial fibrillation occurrence and progression]. Zaporozhye medical journal, 23(6), 845-850. https://doi.org/10.14739/2310-1210.2021.6.232397 [in Ukrainian].

Ogawa, H., An, Y., Ikeda, S., Aono, Y., Doi, K., Ishii, M., Iguchi, M., Masunaga, N., Esato, M., Tsuji, H., Wada, H., Hasegawa, K., Abe, M., Lip, G., Akao, M., & Fushimi AF Registry Investigators. (2018). Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. Stroke, 49(10), 2301-2308. https://doi.org/10.1161/STROKEAHA.118.021396

Seyed Ahmadi, S., Svensson, A. M., Pivodic, A., Rosengren, A., & Lind, M. (2020). Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovascular Diabetology, 19(1), Article 9. https://doi.org/10.1186/s12933-019-0983-1

Verdecchia, P., Angeli, F., & Reboldi, G. (2018). Hypertension and Atrial Fibrillation: Doubts and Certainties From Basic and Clinical Studies. Circulation Research, 122(2), 352-368. https://doi.org/10.1161/CIRCRESAHA.117.311402

Published

2022-05-30

How to Cite

1.
Hrebenyk MV, Honcharyk YV. Factors aggravating the course of atrial fibrillation in comorbid hypertension and type 2 diabetes mellitus. Zaporozhye medical journal [Internet]. 2022May30 [cited 2024Feb.24];24(3):273-8. Available from: http://zmj.zsmu.edu.ua/article/view/253819

Issue

Section

Original research